| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.079 | 0.009 |
| mRNA | SMER-3 | CTRPv2 | pan-cancer | AAC | 0.098 | 0.009 |
| mRNA | SN-38 | CTRPv2 | pan-cancer | AAC | 0.093 | 0.01 |
| mRNA | NPC-26 | CTRPv2 | pan-cancer | AAC | 0.099 | 0.01 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.082 | 0.01 |
| mRNA | KHS101 | CTRPv2 | pan-cancer | AAC | 0.092 | 0.01 |
| mRNA | prochlorperazine | CTRPv2 | pan-cancer | AAC | 0.091 | 0.01 |
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | 0.084 | 0.01 |
| mRNA | BRD4132 | CTRPv2 | pan-cancer | AAC | 0.093 | 0.01 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.08 | 0.01 |